AU2017256774B2 - Semaglutide in cardiovascular conditions - Google Patents

Semaglutide in cardiovascular conditions Download PDF

Info

Publication number
AU2017256774B2
AU2017256774B2 AU2017256774A AU2017256774A AU2017256774B2 AU 2017256774 B2 AU2017256774 B2 AU 2017256774B2 AU 2017256774 A AU2017256774 A AU 2017256774A AU 2017256774 A AU2017256774 A AU 2017256774A AU 2017256774 B2 AU2017256774 B2 AU 2017256774B2
Authority
AU
Australia
Prior art keywords
semaglutide
mace
placebo
subject
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017256774A
Other languages
English (en)
Other versions
AU2017256774A1 (en
Inventor
Oluf Kristian Højbjerg HANSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017256774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2017256774A1 publication Critical patent/AU2017256774A1/en
Application granted granted Critical
Publication of AU2017256774B2 publication Critical patent/AU2017256774B2/en
Priority to AU2024227113A priority Critical patent/AU2024227113A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
AU2017256774A 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions Active AU2017256774B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227113A AU2024227113A1 (en) 2016-04-28 2024-10-04 Semaglutide in cardiovascular conditions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16167458.5 2016-04-28
EP16167458 2016-04-28
EP16188262.6 2016-09-12
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227113A Division AU2024227113A1 (en) 2016-04-28 2024-10-04 Semaglutide in cardiovascular conditions

Publications (2)

Publication Number Publication Date
AU2017256774A1 AU2017256774A1 (en) 2018-11-01
AU2017256774B2 true AU2017256774B2 (en) 2024-07-11

Family

ID=58668875

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017256774A Active AU2017256774B2 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions
AU2024227113A Pending AU2024227113A1 (en) 2016-04-28 2024-10-04 Semaglutide in cardiovascular conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227113A Pending AU2024227113A1 (en) 2016-04-28 2024-10-04 Semaglutide in cardiovascular conditions

Country Status (24)

Country Link
US (3) US20190134162A1 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507394B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107476A1 (en) * 2011-02-09 2012-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CA2797310C (en) * 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
ES2626013T3 (es) * 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107476A1 (en) * 2011-02-09 2012-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
RU2018140900A3 (enExample) 2020-09-28
CA3022535A1 (en) 2017-11-02
KR102778218B1 (ko) 2025-03-10
HUE060040T2 (hu) 2023-01-28
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
JP2019514925A (ja) 2019-06-06
AU2017256774A1 (en) 2018-11-01
WO2017186896A1 (en) 2017-11-02
MY202967A (en) 2024-05-31
ZA202507395B (en) 2025-09-25
EP3448416A1 (en) 2019-03-06
CN109069589A (zh) 2018-12-21
BR112018072020A2 (pt) 2019-02-12
SI3448416T1 (sl) 2022-10-28
CL2018003045A1 (es) 2018-12-14
KR20250038818A (ko) 2025-03-19
HRP20221150T1 (hr) 2022-11-25
AU2024227113A1 (en) 2024-10-31
MA44762A (fr) 2019-03-06
PL3448416T3 (pl) 2022-11-07
DK3448416T3 (da) 2022-10-03
MX2018012700A (es) 2019-01-30
ES2928007T3 (es) 2022-11-14
RS63630B1 (sr) 2022-10-31
EP3448416B1 (en) 2022-08-10
CN109069589B (zh) 2022-09-06
IL262390A (en) 2018-12-31
US20250288649A1 (en) 2025-09-18
JP7221694B2 (ja) 2023-02-14
PH12018502274A1 (en) 2019-09-09
KR20220147712A (ko) 2022-11-03
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
ZA202507394B (en) 2025-09-25
KR20180135012A (ko) 2018-12-19
RU2018140900A (ru) 2020-05-28
PH12018502274B1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US20250262281A1 (en) Semaglutide in Cardiovascular Conditions
US12233114B2 (en) Method for treating diabetes
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
HK1261741A1 (en) Semaglutide in cardiovascular conditions
HK1261741B (en) Semaglutide in cardiovascular conditions
US20190091295A1 (en) Liraglutide in Renal Conditions
WO2018096164A1 (en) Insulin degludec for treating diabetes
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)